Cyclin-Dependent Kinase Inhibitors in Hematological Malignancies—Current Understanding, (Pre-)Clinical Application and Promising Approaches
Genetically altered stem or progenitor cells feature gross chromosomal abnormalities, inducing modified ability of self-renewal and abnormal hematopoiesis. Cyclin-dependent kinases (CDK) regulate cell cycle progression, transcription, DNA repair and are aberrantly expressed in hematopoietic malignan...
Main Authors: | Anna Richter, Nina Schoenwaelder, Sina Sender, Christian Junghanss, Claudia Maletzki |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-05-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/10/2497 |
Similar Items
-
Cyclin-Dependent Kinase 4 and 6 Inhibitors in Cell Cycle Dysregulation for Breast Cancer Treatment
by: Ni Made Pitri Susanti, et al.
Published: (2021-07-01) -
Inhibitors of Cyclin-Dependent Kinases: Types and Their Mechanism of Action
by: Paweł Łukasik, et al.
Published: (2021-03-01) -
Breast Cancer Resistance to Cyclin-Dependent Kinases 4/6 Inhibitors: Intricacy of the Molecular Mechanisms
by: Bin Wang, et al.
Published: (2021-05-01) -
Molecular evidence for increased antitumor activity of gemcitabine in combination with a cyclin-dependent kinase inhibitor, P276-00 in pancreatic cancers
by: Rathos Maggie J, et al.
Published: (2012-08-01) -
Targeting cell cycle regulators in hematologic malignancies
by: Eiman eAleem, et al.
Published: (2015-04-01)